Saenger P

Language: English
References: 0
Page: 42
PDF size: 46.42 Kb.

Text Extraction

Children with ISS have a growth disorder of currently unknown and likely heterogeneous etiology. Short stature in ISS is of similar severity to other growth disorders (eg GH defic, GHD and Turner Syndrome, TS).The FDA approved in 2003 GH for ISS at a dose of 0.37 mg/kg/wk. ISS was defined as a height of -2.25 SDS and it is associated with growth rates unlikely to permit the attainment of adult height in the normal range. Of more than 40 studies conducted with regard to GH in ISS three large studies will be reviewed in this overview.